149 related articles for article (PubMed ID: 30407148)
21. Use of IC tags in short-term carcinogenicity study on CB6F1 TGrasH2 mice.
Urano K; Suzuki S; Machida K; Sawa N; Eguchi N; Kikuchi K; Fukasawa K; Taguchi F; Usui T
J Toxicol Sci; 2006 Dec; 31(5):407-18. PubMed ID: 17202757
[TBL] [Abstract][Full Text] [Related]
22. Di(2-ethylhexyl)phthalate induces hepatocellular adenoma in transgenic mice carrying a human prototype c-Ha-ras gene in a 26-week carcinogenicity study.
Toyosawa K; Okimoto K; Kobayashi I; Kijima K; Kikawa E; Kohchi M; Koujitani T; Tanaka K; Matsuoka N
Toxicol Pathol; 2001; 29(4):458-66. PubMed ID: 11560251
[TBL] [Abstract][Full Text] [Related]
23. Twenty-six-week oral carcinogenicity study of 3-monochloropropane-1,2-diol in CB6F1-rasH2 transgenic mice.
Lee BS; Park SJ; Kim YB; Han JS; Jeong EJ; Son HY; Moon KS
Arch Toxicol; 2017 Jan; 91(1):453-464. PubMed ID: 27017489
[TBL] [Abstract][Full Text] [Related]
24. Lung Tumor Induction by 26-week Dermal Application of 1,2-Dichloroethane in CB6F1-Tg rasH2 Mice.
Suguro M; Numano T; Kawabe M; Doi Y; Imai N; Mera Y; Tamano S
Toxicol Pathol; 2017 Apr; 45(3):427-434. PubMed ID: 28421967
[TBL] [Abstract][Full Text] [Related]
25. Regulatory Forum Opinion Piece*: Retrospective Evaluation of Doses in the 26-week Tg.rasH2 Mice Carcinogenicity Studies: Recommendation to Eliminate High Doses at Maximum Tolerated Dose (MTD) in Future Studies.
Paranjpe MG; Denton MD; Vidmar TJ; Elbekai RH
Toxicol Pathol; 2015 Jul; 43(5):611-20. PubMed ID: 25391312
[TBL] [Abstract][Full Text] [Related]
26. A Proposal for New Strategies in Dose Selection for 26-Week Tg.Rash2 Carcinogenicity Studies.
Paranjpe MG; Vidmar TJ; Denton MD; Elbekai RH; Mann PC; Mckeon M; Brown C; Martineck J
Int J Toxicol; 2021; 40(4):311-321. PubMed ID: 33783262
[TBL] [Abstract][Full Text] [Related]
27. The rasH2 transgenic mouse: nature of the model and mechanistic studies on tumorigenesis.
Tamaoki N
Toxicol Pathol; 2001; 29 Suppl():81-9. PubMed ID: 11695564
[TBL] [Abstract][Full Text] [Related]
28. Twenty-six week carcinogenicity study of ampicillin in CB6F1-TgrasH2 mice.
Adachi T; Kuwamura Y; Fujiwara T; Tanimoto N; Nishimura T; Koguchi A; Kobayashi K; Sasaki Y; Yamaguchi C; Honda T; Kawashima K; Yuasa H; Yamamura T; Inui T
J Toxicol Sci; 2002 Aug; 27(3):147-63. PubMed ID: 12238139
[TBL] [Abstract][Full Text] [Related]
29. Carcinogenicity evaluation: comparison of tumor data from dual control groups in the CD-1 mouse.
Baldrick P; Reeve L
Toxicol Pathol; 2007 Jun; 35(4):562-9. PubMed ID: 17562489
[TBL] [Abstract][Full Text] [Related]
30. A 26-week carcinogenicity study of 2-amino-3-methylimidazo[4,5-f]quinoline in rasH2 mice.
Okamura M; Moto M; Muguruma M; Ito T; Jin M; Kashida Y; Mitsumori K
Toxicol Pathol; 2006; 34(2):199-205. PubMed ID: 16537296
[TBL] [Abstract][Full Text] [Related]
31. Reduction in the number of animals and the evaluation period for the positive control group in Tg.rasH2 short-term carcinogenicity studies.
Shah SA; Paranjpe MG; Atkins PI; Zahalka EA
Int J Toxicol; 2012; 31(5):423-9. PubMed ID: 22988008
[TBL] [Abstract][Full Text] [Related]
32. CB6F1-rasH2 mouse: overview of available data.
Usui T; Mutai M; Hisada S; Takoaka M; Soper KA; McCullough B; Alden C
Toxicol Pathol; 2001; 29 Suppl():90-108. PubMed ID: 11695565
[TBL] [Abstract][Full Text] [Related]
33. Validation of transgenic mice harboring the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing.
Yamamoto S; Urano K; Nomura T
Toxicol Lett; 1998 Dec; 102-103():473-8. PubMed ID: 10022298
[TBL] [Abstract][Full Text] [Related]
34. Proposal to Eliminate Urethane-Treated Positive Control Dose Groups in 26-Week Tg.rasH2 Carcinogenicity Studies.
Paranjpe MG; Rudmann D; Sargeant A; Morse M; Yonpiam R; Bonnette K; Albretsen J; Papagiannis C
Int J Toxicol; 2021; 40(3):207-210. PubMed ID: 33813924
[TBL] [Abstract][Full Text] [Related]
35. An FDA overview of rodent carcinogenicity studies of angiotensin II AT-1 receptor blockers: pulmonary adenomas and carcinomas.
Link WT; De Felice A
Regul Toxicol Pharmacol; 2014 Nov; 70(2):555-63. PubMed ID: 25223563
[TBL] [Abstract][Full Text] [Related]
36. 26-Week carcinogenicity study of di-isodecyl phthalate by dietary administration to CB6F1-rasH2 transgenic mice.
Cho WS; Jeong J; Choi M; Park SN; Han BS; Son WC
Arch Toxicol; 2011 Jan; 85(1):59-66. PubMed ID: 20358181
[TBL] [Abstract][Full Text] [Related]
37. [Background data of spontaneous tumors in F344/DuCrlCrlj rats].
Takanobu K; Aiso S; Umeda Y; Senoh H; Saito M; Katagiri T; Ikawa N; Ishikawa H; Mine T; Take M; Haresaku M; Matsumoto M; Fukushima S
Sangyo Eiseigaku Zasshi; 2015; 57(3):85-96. PubMed ID: 25753608
[TBL] [Abstract][Full Text] [Related]
38. Results from oral gavage carcinogenicity studies of ruxolitinib in Tg.rasH2 mice and Sprague-Dawley (Crl:CD) rats.
Shuey DL; Oliver J; Zhou G; Roberts A
Regul Toxicol Pharmacol; 2016 Nov; 81():305-315. PubMed ID: 27647628
[TBL] [Abstract][Full Text] [Related]
39. The Antitussive Benzonatate Is Not Tumorigenic in Rodent Carcinogenicity Studies.
Teo S; Paranjpe M; Mckeon M; Mann P; Lee S; LaRock R; Brown T
Toxicol Pathol; 2018 Aug; 46(6):683-692. PubMed ID: 30033829
[TBL] [Abstract][Full Text] [Related]
40. Carcinogenic comparative study on rasH2 mice produced by two breeding facilities.
Machida K; Urano K; Yoshimura M; Tsutsumi H; Nomura T; Usui T
J Toxicol Sci; 2008 Oct; 33(4):493-501. PubMed ID: 18827450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
